MX2020007271A - Sales y cristales novedosos. - Google Patents
Sales y cristales novedosos.Info
- Publication number
- MX2020007271A MX2020007271A MX2020007271A MX2020007271A MX2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- novel salts
- utan
- quinoxalin
- pyrido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La divulgación provee formas de sal clorhidrato nuevas, farmacéuticamente aceptables, de 1-(4-fluoro-fenil)-4-((6bR,10aS)- 3-metil-2,3,6b,9,10,10a-hexahidro-1H,7H-pirido[3',4':4,5]pirrolo[ 1,2,3-de]quinoxalin-8-il)-butan-1-ona, junto con métodos de preparación y uso de las mismas, y composiciones farmacéuticas que las comprenden.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762563341P | 2017-09-26 | 2017-09-26 | |
PCT/US2018/052922 WO2019067591A1 (en) | 2017-09-26 | 2018-09-26 | NEW SALTS AND CRYSTALS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007271A true MX2020007271A (es) | 2020-08-17 |
Family
ID=65903143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007271A MX2020007271A (es) | 2017-09-26 | 2018-09-26 | Sales y cristales novedosos. |
Country Status (6)
Country | Link |
---|---|
US (2) | US11440911B2 (es) |
EP (1) | EP3687535A4 (es) |
JP (1) | JP2020535231A (es) |
CN (1) | CN111107847A (es) |
MX (1) | MX2020007271A (es) |
WO (1) | WO2019067591A1 (es) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1192165B1 (en) | 1999-06-15 | 2004-09-22 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
BR0116429A (pt) | 2000-12-20 | 2006-05-09 | Bristol Myers Squibb Co | piridoindóis substituìdos como agonistas e antagonistas da serotonina |
US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
WO2002085838A1 (en) | 2001-04-24 | 2002-10-31 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
BRPI0412763A (pt) | 2003-07-21 | 2006-09-26 | Smithkline Beecham Corp | formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios |
JP2009541385A (ja) * | 2006-06-27 | 2009-11-26 | サンド・アクチエンゲゼルシヤフト | 塩の製造のための新規な方法 |
CN101796051B (zh) | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
EP2175724A4 (en) | 2007-08-01 | 2010-09-15 | Medivation Neurology Inc | METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY |
ES2530090T3 (es) * | 2008-03-12 | 2015-02-26 | Intra-Cellular Therapies, Inc. | Sólido de gamma-carbolinas fusionadas con heterociclo sustituido |
USRE48839E1 (en) | 2008-05-27 | 2021-12-07 | Intra-Cellular Therapies, Inc | Methods and compositions for sleep disorders and other disorders |
CA2796756A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders |
CA2870303A1 (en) * | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
HUE053159T2 (hu) | 2013-03-15 | 2021-06-28 | Intra Cellular Therapies Inc | Szerves vegyületek |
DK3076967T3 (da) | 2013-12-03 | 2021-10-25 | Intra Cellular Therapies Inc | Fremgangsmåder til behandling af residuelle symptomer på skizofreni |
EP3125893B1 (en) | 2014-04-04 | 2023-09-20 | Intra-Cellular Therapies, Inc. | Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors |
WO2017165843A1 (en) | 2016-03-25 | 2017-09-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
PL3497104T3 (pl) | 2016-08-09 | 2022-02-21 | Teva Pharmaceuticals International Gmbh | Postacie w stanie stałym soli ditosylanowej lumateperonu |
US10716786B2 (en) | 2017-03-24 | 2020-07-21 | Intra-Cellular Therapies, Inc. | Transmucosal and subcutaneous compositions |
CN110636845A (zh) | 2017-04-10 | 2019-12-31 | 雷迪博士实验室有限公司 | 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体 |
WO2019102240A1 (en) | 2017-11-27 | 2019-05-31 | Egis Gyógyszergyár Zrt. | Method for the manufacture of lumateperone and its salts |
JP7483671B2 (ja) | 2018-06-11 | 2024-05-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ-カルボリン類合成 |
-
2018
- 2018-09-26 MX MX2020007271A patent/MX2020007271A/es unknown
- 2018-09-26 US US16/649,515 patent/US11440911B2/en active Active
- 2018-09-26 CN CN201880061554.9A patent/CN111107847A/zh active Pending
- 2018-09-26 EP EP18860411.0A patent/EP3687535A4/en active Pending
- 2018-09-26 JP JP2020538775A patent/JP2020535231A/ja active Pending
- 2018-09-26 WO PCT/US2018/052922 patent/WO2019067591A1/en unknown
-
2022
- 2022-07-28 US US17/815,843 patent/US20220363682A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3687535A1 (en) | 2020-08-05 |
US20200247805A1 (en) | 2020-08-06 |
US20220363682A1 (en) | 2022-11-17 |
WO2019067591A1 (en) | 2019-04-04 |
JP2020535231A (ja) | 2020-12-03 |
EP3687535A4 (en) | 2021-06-09 |
US11440911B2 (en) | 2022-09-13 |
CN111107847A (zh) | 2020-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020013116A (es) | Sales y cristales novedosos. | |
MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
MX2022010797A (es) | Composiciones novedosas y metodos. | |
CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
MX2018015422A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridini lo. | |
SA521430638B1 (ar) | H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية | |
PH12016501355B1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
PH12018500047B1 (en) | Notch pathway signaling inhibitor compounds | |
MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
PH12017501816A1 (en) | Azabensimidazoles and their use as amp a receptor modulators | |
MY192216A (en) | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine | |
TW201613864A (en) | Novel compounds | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MX2022013274A (es) | Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util. | |
MY194711A (en) | Novel annelated phenoxyacetamides | |
MX2014013664A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. | |
NZ763341A (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
MX2021006886A (es) | Dispersiones solidas amorfas. | |
PH12018501563A1 (en) | Indane derivatives as mglur7 modulators | |
MX2020007271A (es) | Sales y cristales novedosos. | |
PH12020551736A1 (en) | The crystalline forms of a compound |